Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
Practice environmental safety in Style: Divulging Famous Electric Vehicle Brands- Hezbollah sees potential win as Israel backs down from disarmament goal
- Favored Chinese Dish: Make Your Determination
- The most effective method to Go with Informed Choices on Vehicle Leases
- Two Passover initiatives target isolation and safety for Israel’s elderly
- Reporter's notebook: Inside the IDF’s ‘Hamas Village,’ and how Israel is rewriting urban warfare
- The newest 'Project Hail Mary' trailer shows Ryan Gosling befriending an alien in Phil Lord and Chris Miller's space epic
- Italian police hold suspected boss of Naples Mafia's Mazzarella Clan
- Ethiopian earthquakes and volcanic eruptions: earth scientist explains the link
